3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
6
Carcinoma, Renal Cell
5
Carcinoma, Transitional Cell
3
Thyroid Neoplasms
2
Prostatic Neoplasms
2
Nasopharyngeal Carcinoma
2
Clear-cell metastatic renal cell carcinoma
2
Vulvar Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Urachal adenocarcinoma
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Somatostatinoma
1
Seminoma
1
Sarcoma
1
Rectal Neoplasms
1
Rare Diseases
1
Pseudomyxoma Peritonei
1
Pheochromocytoma
1
Perivascular Epithelioid Cell Neoplasms
1
Penile Neoplasms
1
Parathyroid Neoplasms
1
Paranasal Sinus Neoplasms
1
Paraganglioma
1
Paget Disease, Extramammary
1
Ovarian Neoplasms
1
Osteosarcoma
1
Interventions
X-Rays
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Biopsy
4
ulixertinib
2
tipifarnib
2
selpercatinib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
tazemetostat
1
talazoparib
1
palbociclib
1
olaparib
1
irinotecan sucrosofate
1
Vemurafenib
1
Temozolomide
1
Pharmacogenomic Variants
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
CTLA-4 Antigen
×
30 days
×
Clear all
No trials found.